Replies to post #403745 on NorthWest Biotherapeutics Inc (NWBO)

[Jack2479]

Exactly why as a long shareholder pre the reverse split and has taken part in the majority of raises is looking aghast at the potential for what this could mean. What I hope for is that they all come together as one company under the NWBO ownership. Just being repaid any amounts invested won’t cut it as we took all the risk without a certificate and Advent have a certificate they are up up and away…..

This is not what I think the meaning of “We are going it alone” statement from Mgt several years ago actually meant. Unless Linda speaks as per Queen Elizabeth….

[Jack2479]

Creditors are small and not named in value but let me re-look at long term liabilities

[Jack2479]

No long term liabilities are listed so everything is contained in creditors all due within one year…..

[Know-Fear]

Cognate included NWBO ready infrastructure. At preset does Advent have possession (own) any NWBO ready infrastructure?

[biosectinvestor]

Still at it? Even though people know you are just making noise at this point?

It isn’t another anything, but the first situation wasn’t what it was said to be either. Neither is what you are saying they are or will be.

But the two circumstances are, in fact, different. And it doesn’t matter if the backers ultimately sell Advent any more than it mattered that Cognate was sold.

Did NWBO need to be sold with Cognate to make it valuable? You argued the other day that NWBO had no value without Advent, which is false. Obviously that was not the reality with Cognate, but Cognate was a free standing CDMO. Advent is not. Sawston does not belong to it.

But the reality is that having that role worked modularity is a useful development tool and it makes some of the burdens less onerous for NWBO. Which I have explained elsewhere.

And there simply is not much value or margin to be made in contract manufacturing. It’s really not where the value is, at all. It is a burdensome and expensive task, filled with potential risks and downsides and it his human resource heavy. And in this case, and generally, all the IP also belongs to the customer, so there is no accretive value in IP.

[biosectinvestor]

The company has explained why they want to utilize space not yet able to be used. And the contract mechanisms for work done in the space is subject to NWBO’s approval. They have access to it.

This is a symbiotic and fluid situation, but the facilities all belong to NWBO. Advent has access to the excess capacity for now, and NWBO will be paid for the use of that capacity. But, NWBO has ultimate say regarding the use of Sawston.